Vaxxinity, Inc. (VAXX) |
|
1.74 0 (0%)
|
11-25 12:56 |
|
Open: |
1.74 |
Pre. Close: |
1.74 |
|
High:
|
1.7455 |
Low:
|
1.7 |
|
Volume:
|
10,993 |
Market Cap:
|
195(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 8:52:19 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.41 One year: 2.82 |
| Support: |
Support1: 1.56 Support2: 1.25 |
| Resistance: |
Resistance1: 2.06 Resistance2: 2.41 |
| Pivot: |
1.6  |
| Moving Average: |
MA(5): 1.74 MA(20): 1.54
MA(100): 1.91 MA(250): 3.68 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 57.3 %D(3): 58.4 |
| RSI: |
RSI(14): 56.3 |
| 52-week: |
High: 10.56 Low: 1.25 |
| Average Vol(K): |
3-Month: 174 (K) 10-Days: 144 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VAXX ] has closed below upper band by 28.1%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.75 - 1.76 |
1.76 - 1.76 |
|
Low:
|
1.68 - 1.69 |
1.69 - 1.7 |
|
Close:
|
1.72 - 1.74 |
1.74 - 1.75 |
|
Company Description |
|
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas. |
Headline News |
Sat, 26 Nov 2022
Died Suddenly Review: This anti-vaccine documentary needs to die suddenly - DailyO
Thu, 24 Nov 2022
Montana Supreme Court upholds anti-vaxx law for now, but sends the case back to district court – Daily Montanan - Daily Montanan
Wed, 23 Nov 2022
Nearly 40million children missed a measles vaccine last year amid lockdowns and anti-vaxx movement - Daily Mail
Tue, 22 Nov 2022
Letitia Wright Responds to 'THR' Story, Anti-Vaxx Statements - Vulture
Mon, 21 Nov 2022
RCMP monitored hostility from anti-vaxx movement against PM - CTV News
Mon, 21 Nov 2022
GO-VAXX bus heading to Angus on Tuesday - BarrieToday
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
112 (M) |
|
% Held by Insiders
|
3.174e+007 (%) |
|
% Held by Institutions
|
55.9 (%) |
|
Shares Short
|
984 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.2183e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-250 |
|
Return on Assets (ttm)
|
985.7 |
|
Return on Equity (ttm)
|
-67.2 |
|
Qtrly Rev. Growth
|
49000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-72 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
2896.19 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
850870 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
